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ABSTRACT: The long-term survival of the Hodgkin’s 
lymphoma patients treated at an early age with chemoradiotherapy 
is	raising	awareness	for	the	late	effects	of	this	treatment.	Radio-
induced breast cancer is one of the described risks and occurs 
almost exclusively after a period of 10 years. Well-established 
risk factors include the diagnosis in the 10-16 age group, the use 
of	extended-field	radiation	therapy	and	an	increase	in	radiation	
dose. Conservative breast surgery with adjuvant radiotherapy is 
feasible, but dose-reduction techniques to organs at risk should 
be considered, given the previous irradiation. We report a clinical 
case of a secondary breast cancer in a patient who underwent 
chemoradiotherapy, with mantle field radiation therapy, for 
supradiaphragmatic Hodgkin’s lymphoma at youth. After 
multidisciplinary discussion and given the patient’s willingness 
to preserve the breast, she was treated with conservative breast 
surgery and adjuvant radiotherapy. 
Keywords: Radiation-induced malignancies; Breast cancer; 
Hodgkin’s lymphoma.
RESUMO: A sobrevida longa das pacientes com linfoma 
de Hodgkin submetidas a quimioradioterapia numa idade 
precoce tem evidenciado os efeitos tardios deste tratamento. 
O desenvolvimento de cancro da mama radio-induzido é um 
dos riscos descritos, ocorrendo quase exclusivamente após um 
intervalo de 10 anos do tratamento. A idade ao diagnóstico entre 
os 10-16 anos, a radioterapia de campo amplo e um aumento da 
dose prescrita são os fatores de risco estabelecidos. A cirurgia 
conservadora da mama com radioterapia adjuvante é exequível, 
mas, dada a irradiação prévia, devem ser equacionadas estratégias 
de redução de dose nos órgãos de risco. Apresenta-se o caso de 
cancro da mama secundário numa paciente submetida em jovem 
a quimioradioterapia, com técnica de irradiação em manto, 
por linfoma de Hodgkin supradiafragmático. Após discussão 
multidisciplinar e dada a vontade da paciente em preservar a 
mama, foi tratada com cirurgia conservadora e radioterapia 
adjuvante. 
Palavras-chave: Tumores radio-induzidos; Cancro da mama; 
Linfoma de Hodgkin.
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INTRODUCTION
Radiotherapy is required in at least 40% of all curative therapeutic strategies in oncology1. 
In Hodgkin’s lymphoma treatment, in association with 
chemotherapy, it leads to an overall and relative survival of 
89.6% and 94.3% at 5 years, respectively2. Given the higher 
incidence of Hodgkin’s lymphoma in the 20-40 age group, 
the	late	effects	of	the	treatment	are	of	particular	concern3, 
4.	The	 irradiation	 field	 for	 supradiaphragmatic	 disease	
includes organs at risk such as the heart, esophagus, lungs 
and thyroid and, particularly in the case of female patients, 
the mammary glands. Risks include cardiovascular disease, 
endocrinopathies and the development of secondary 
tumors5. Secondary breast cancer in patients treated at a 
young	 age	 (≤	30	years)	 is	 the	most	 common	 secondary	
tumor4, with a risk of death from breast cancer twice as 
high as patients with spontaneous breast cancer5.
CLINICAL CASE
A 47-year-old female patient with a history of 
Nodular Sclerosing Hodgkin lymphoma, stage IIA, 
presented as a left cervical adenopathy at 19 years old. 
She was treated with chemotherapy (4 cycles of ABVD 
regimen) followed by mantle field irradiation, which 
included cervical, axillar and mediastinal regions (with 
consequent irradiation by unquantified dose in the 
mammary glands bilaterally), with telecobalt therapy, with 
the total treatment dose at point A of 35.6 Gy1 (2.5 Gy per 
fraction prescribed to the skin per session). 1 Gray: unit 
of ionizing radiation dose in the International System of 
Units corresponding to the energy absorbed per unit mass
The patient had smoking habits since she was 
19	years	 old,	 quantified	 in	 21	UMA.	She	had	 a	 history	
of	3	pregnancies	(the	first	at	29	years	old)	and	was	pre-
menopausal. She used oral contraceptives for 14 years and 
posteriorly placed a copper intrauterine device. She had no 
family history of cancer, namely breast cancer.
She underwent routine mammograms irregularly. In 
December 2014, a suspicious lesion in the upper quadrants 
of the left breast appeared on a mammogram. The patient 
had occasional complaints of a “stinging” sensation in 
her left breast. On physical examination, a suspicious 
hardened area was palpable in the upper-outer quadrant. 
Suspicious lymph nodes were also palpable in the ipsilateral 
axilla. Mammography showed a dense area with a spiky 
appearance in the upper-outer quadrant of the left breast 
(BI-RADS V). On ultrasound examination, a solid lesion 
with irregular edges and 18 mm of greatest diameter 
was observed (BI-RADS V) (Figure 1). The patient was 
submitted to a core needle biopsy guided by ultrasound. In 
magnetic resonance imaging (MRI) evaluation, the lesion 
measured approximately 20x11 mm, 0.5 cm from the skin, 
7 cm from the nipple and 7 cm from the chest wall (Figure 
2). In ipsilateral axillary region, three pathologic lymph 
nodes, varying in size between 17 and 20 mm, were seen. 
A surgical clip was placed in primary tumor.
Figure 1: Breast mammography (left) and breast ultrasound (right) at diagnosis
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Figure 2: Breast MRI at diagnosis, using the SPAIR fat 
suppression technique
Biopsy revealed an invasive carcinoma NST (of no 
special type), grade 2, in about 80% of the sample, with 
estrogen receptors with moderate intensity marking in 
80% of tumor cells and progesterone with strong intensity 
marking in 90% of tumor cells, HER2 negative status 
(1+) by immunohistochemistry, with a proliferative index 
(Ki-67)	of	85%	and	negative	p53	expression,	classified	as	
a	luminal	B	molecular	subtype.	The	fine-needle	aspiration	
cytology of one of the pathologic lymph nodes revealed the 
presence of metastasis compatible with breast carcinoma.
Computed tomography (CT) of the chest and 
abdominal ultrasound did not found distant metastasis.
The	clinical	 stage	was	defined	as	 IIB	 (cT1c	cN1	
cM0).
The therapeutic strategy was decided by a 
multidisciplinary team and took into account the patient’s 
desire to preserve the breast. It was highlighted that even 
after mastectomy, the patient probably needed post-
mastectomy radiotherapy (particularly targeting the high-
risk lymph node regions, taking into account the presence 
of axillary metastasis), and so the mastectomy did not 
eliminate posterior re-irradiation. It was also highlighted 
that breast reconstruction after mastectomy is concerning 
in a previously irradiated patient, with high rates of 
postoperative complications. The patient didn’t have any 
late skin toxicity from previous irradiation, which gave 
support to a conservative strategy. The patient was warned 
of the risks of re-irradiation, including the possible poor 
cosmetic result, and with the agreement of the medical team 
choose a breast conserving surgery.
Neoadjuvant chemotherapy was initiated with four 
dose-dense cycles of doxorubicin and cyclophosphamide 
(AC regimen) followed by twelve cycles of paclitaxel, with 
good overall tolerance. After six weeks, she underwent a 
left breast tumorectomy with ipsilateral axillary lymph node 
dissection. The anatomopathological result of the surgical 
specimen showed a residual invasive carcinoma with 9 
mm of greatest diameter, with a distance of 1 mm to the 
closest margins (upper and posterior). Of the twelve lymph 
nodes removed, one had micrometastasis. The pathological 
staging was ypT1bN1mi.
After eight weeks, the patient received 3D 
conformal radiation therapy (3D CRT) targeting the left 
breast and the high-risk lymph node regions with a dose of 
50 Gy, followed by a boost in the tumor bed, completing the 
total prescribed dose of 66 Gy, 2 Gy per fraction (Figure 3).
Figure 3: Target volumes and organs at risk delineation in axial, coronal and sagittal sections (from left to right, respectively)
The patient presented grade 2 radiodermatitis in the 
inframammary fold, axillary and supraclavicular region, 
treated	with	 oral	 non-steroidal	 anti-inflammatory	 drugs	
and application of Mepilex® Lite dressing.
She was under hormone therapy with tamoxifen for 
two years, followed by letrozole after menopause, which 
she has maintained since then with good tolerance.
One year and six months after the end of radiotherapy, 
the patient complicated with deep vein thrombosis of 
the left upper limb. She started anticoagulation with 
low-molecular-weight heparin (LMWH), with clinical 
improvement.
At the date of the last follow-up visit, two years and 
six months after radiotherapy, the patient was asymptomatic 
and in the MRI assessment she did not present any 
suspicious lesion. On physical examination, an area of 
telangiectasias,	edema	and	fibrosis	of	the	left	breast	were	
observed. She maintained an ipsilateral upper limb edema, 
but with preserved joint mobility (Figure 4).
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Figure 4:	Photographic	records	of	the	patient	in	a	follow-up	visit	showing	edema	and	fibrosis	of	the	left	breast	and	ipsilateral	upper	
limb (left) and telangiectasias in left axillary region (right)
DISCUSSION
The	 update	 of	 the	Late	Effects	 Study	Group	 in	
Hodgkin’s lymphoma showed that the increase in the 
relative risk of breast cancer in patients that underwent 
radiotherapy	at	young	ages	(≤	30	years)	occurs	after	10	
years, with a median time of 18,1 years. Age at diagnosis 
is one of the main risk factors, particularly the interval 
between 10-16 years, given the greater radiosensitivity of 
the mammary gland cells at the time of puberty4.
The role of chemotherapy in the carcinogenesis of 
these secondary tumors is controversial. Even if the risk 
of secondary tumors also increases in patients undergoing 
chemotherapy alone6, in studies of chemoradiotherapy 
versus radiotherapy alone, the combined therapy seems 
to confer a decrease in this risk7. The likely cause is the 
induction of premature menopause by the use of alkylating 
agents that reduces the risk of developing hormone-
dependent tumors8.
In 2016, Conway et al.9 demonstrated that the 
volume	of	the	irradiation	field	is	a	significant	risk	factor.	
In	this	study,	the	mantle	field	irradiation	increased	the	risk	
of secondary breast cancer by 2.9 (p = 0.004) and 3.3 (p = 
0.01) in comparison to patients undergoing chemotherapy 
only	and	a	smaller	volume	irradiation	field,	respectively.
In	 the	 past,	 as	 exemplified	 by	 our	 case,	 patients	
underwent	 radiotherapy	 using	 the	 classic	mantle	 field	
technique, which includes cervical, axillary and mediastinal 
lymph node regions. Subsequently, a smaller volume 
irradiation	field	 became	 standard	 and	 included	only	 the	
lymph node regions with documented disease – involved 
field	radiotherapy.	In	the	last	decade,	the	use	of	positron	
emission tomography by computed tomography (PET-
CT) allowed the irradiation targeting only the involved 
lymph nodes. However, the fusion of PET-CT images with 
radiotherapy planning CT is compromised, since they are 
usually	obtained	in	different	positions.	An	adaptation	of	this	
technique has gained popularity and includes the location 
of the lymph nodes initially involved, but not the entire 
lymph node region – involved site radiotherapy10.
The telecobalt therapy unit in which our patient 
underwent treatment is outdated and the use of 3D CRT 
with a linear accelerator is the standard nowadays10. Nieder 
et al. published a comparison of dosimetric studies between 
the following techniques: two opposite antero-posterior 
and	postero-anterior	fields,	four	fields	with	3D	CRT	and	
seven	fields	with	 intensity-modulated	 radiation	 therapy	
(IMRT). The coverage of the target volume was similar 
between	 the	 different	 techniques,	 but	 the	 use	 of	 IMRT	
allowed better spare of the heart and a decrease of the higher 
doses in the breast and lung parenchyma. Even though 
heart sparing irradiation with IMRT may contribute to the 
reduction	of	late	cardiovascular	toxicity,	the	benefit	in	the	
breast and lungs parenchyma is more controversial given 
the irradiation of a greater volume with lower doses that 
can be carcinogenic. Age, cardiovascular comorbidities, 
administration of cardiotoxic chemotherapy, individual 
anatomy of the patient and family history of cancer, are 
factors to consider when deciding on the most appropriate 
radiotherapy technique11.
Krul et al. described a linear increase in risk with 
increasing dose with an adjusted odds ratio of 6.1% by 
Gray12. In our case, the total dose received > 30 Gy was 
probably a major risk factor.
In comparison to spontaneous tumors, Alm El-Din et 
al.13 found a higher incidence of bilateral tumors, however 
with the same pathologic characteristics. In contrast, Horst 
et al.14 settled that these secondary breast cancers are 
usually more aggressive, often triple-negative (estrogen and 
progesterone negative receptors and HER2 negative status).
The carcinogenesis of radiation-induced tumors 
is linked to DNA damage and probably to DNA repair 
defects present in genetic polymorphisms of some 
patients. For example, Best et al	 identified	 two	variants	
on chromosome 6q21 that induce a minor expression of 
PRDM1 that downregulates pro-proliferative genes such 
as MYC. The presence of this polymorphism increases the 
risk of secondary tumors in children undergoing radiation, 
but not in adults, which supports the hypothesis of genetic 
susceptibilities that are particularly relevant at younger 
ages15. Nevertheless, mutations in the tumor suppressor 
genes TP53, BRCA1 and BRCA2 are not more frequent in 
survivors of Hodgkin’s lymphoma with secondary tumors16.
The follow-up in our case was not in agreement 
to	current	guidelines.	All	patients	with	≤	40	years	old	at	
the time of chest and / or axillary irradiation should start 
annual mammograms 8 to 10 years after treatment or at 
age	40	(whichever	comes	first).	Patients	with	≤	30	years	
old should start annual breast MRI3,10. The use of both 
imaging modalities improves sensitivity in the diagnosis 
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from 70% to 95%17.
According to Watson et al.18, the tolerance of 
chemotherapy in the treatment of breast cancer in patients 
that already did chemoradiotherapy for Hodgkin’s 
lymphoma seems to be similar to patients without previous 
chemotherapy treatments, so a conventional chemotherapy 
protocol should be the choice. In our case, the patient 
showed good tolerance to chemotherapy.
Given the previous irradiation of thoracic and 
axillary region, radical mastectomy is often the surgical 
option to avoid re-irradiation of the same region. However, 
even	after	radical	mastectomy,	the	patient	can	benefit	from	
adjuvant radiotherapy to the chest wall and lymph node 
regions to increase loco-regional control of the disease. In 
patients that choose to have breast reconstruction surgery, 
this may be particularly problematic considering the rate 
of postoperative complications of up to 69%19.
Haberer et al.20	analyzed	a	significant	group	of	cases	
treated with breast-conserving surgery and showed the 
feasibility of this treatment strategy, without compromising 
loco-regional control, therefore should be considered in 
patients who wish to conserve the breast, as our patient. 
However, the authors recommended strategies to spare 
organs at risk, highlighting the use of unconventional 
positioning as lateral or ventral decubitus position, 
deep inspiration breath-hold technique or breathing- 
synchronized irradiation20. There are also promising results 
with the use of intraoperative partial breast irradiation in 
women who had previously been irradiated21,22. However, 
the feasibility of the patient positions and advanced 
techniques described above have to be assessed on a case-
by-case basis, as there may be anatomical or compliance 
limitations.
In a study of seventy-one Hodgkin’s lymphoma 
survivors treated for secondary breast cancer, mostly with 
mastectomy, Wolden et al.23 reported a similar prognosis 
compared to the general population, with 10-year overall 
survival rate of 88% for stage I. In this study, only two 
patients were treated with breast-conserving surgery, one 
of which developed soft tissue necrosis in the breast due 
to re-irradiation.
CONCLUSIONS
Chemoradiotherapy is the standard treatment for 
localized Hodgkin’s lymphoma, associated with overall 
survival gain. Given the higher prevalence of this disease 
at	younger	ages,	 the	 late	effects	of	 this	 treatment	are	of	
particular concern and need tailored surveillance. We 
highlight the risk of radio-induced tumors, particularly the 
most common secondary breast cancer. The age at diagnosis, 
the	volume	of	the	irradiation	field	and	the	prescribed	dose	
are established risk factors. Breast conserving surgery with 
adjuvant radiotherapy is feasible, without compromising 
local control, even though therapeutic decision must always 
be personalized and changes in the patient position and use 
of advanced radiotherapy techniques must be considered.
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